EXHIBIT A

	Pat.	, <u>.</u>		=	10	9	00	7	6	6	5	4		2	-	Pat.
	Initials	7 5	D.	BJW	APT	PK	AJB	JA	MJC	ALK	×	I]	×	2	Initials
·	Date of	14/1/83	31/5/82	5/10/95	26/4/95	3/1/67	24/5/97	20/8/49	25/9/74	6/12/91	22/5/94	3/3/95	13/5/85	3/8/95	26/5/89	Date of birth
	Diagnosis	Eczema	Hand dermatitis Due to shampoos	Eczema since 8 weeks	Eczema since 6 weeks	Mild eczerna	Eczema since 2-3 weeks old	Eczema since teenager	Atopic eczema since childhood	Eczema since 5 weeks old	Atopic eczema since 21 months old	Atopic eczema since 3-4 weeks old	months old,	Atopic dermatitis soon after birth	Atopic dermatitis since 18 months old	Diagnosis
	Date	September 2000	March 2000	February 1999	May 1999	November 1999	November 1999	February 1999	December 1998	December 1997	November 1998	September 1998	June 1998	December 1997	December 1997	Date commenced treatment
	Concentration	4% lotion	4% lotion	4% lotion	4% lotion	2% lotion	2% lotion	4% lotion	4% lotion	7.5% lotion 5% foam	4% lotion	4% lotion	4% lotion	5% foam 7.5% lotion	7.5% and 4% lotions	Concentration of Altoderm
	Concomitant	Steroids		ds wrapping	Steroids	None	Hydrocortisone	Steroid creams	Hydrocortisone 1%	Eumovate	Wet wrapping and Eumovate	Aureocort when bad Otherwise Eumovate.	Calmurid cream x 2 daily	Unguent Merck 1% Hydrocortisone	Hydrocortisone 1%	Concomitant treatment
ecetved from < 6	Notes 339	continuing to use	Dermatitis improved. Has had 2 flare ups needing additional steroig otherwise controlled on Altoderm alone. Continues as trainee haired Last contact July 2001 – still OK with Altoderm	Skin improved. Altoderm caused hot sensation during flare up. OKe restarted after flure-up treated with steroids. No contact since June	Skin improved but discontinued	No benefits from Altoderm. Discontinued	Skin improved. Altoderm well tolerated. Left for Australia Dec 19 a Eczema cleared in Australia. No further treatment required	Made itching worse for first few days. Then skin improved. By Ap skin normal on Altoderm alone. Not needing steroids. Last contact Jan. 2003 -still:OK	30/12/98: Eczema mainly on arms, neck, thighs. 7/1/99: Skin improved. Subsequently lost to follow up	Initial improvement but 7.5% lotion later caused stinging. Transferre 5% foam without problems. Treatment stopped as no longer require	8/12/98. Skin initially improved after starting Altoderm. Then develope severe asthma attack (needed oral steroids). Altoderm started to causensation so was stopped. Not tried again	20998: Skin considerably better after using Altoderm for one week. 209988. Started cold and had flare up of eczema. Skin very red and Altoderm caused hot feeling. Stopped and used Aureocort. Skin sell and after 24 hours was able to use Altoderm without problems. Con to use Altoderm with benefit.	Eczema affects hands. Improved after starting Altoderm 4%. Continuse with benefit		7.5% effective and well tolerated. Eczerna improved. Itching recommenced 2 days after stopping Altoderm. 4/3/98: Transferred I. Altoderm. Eczerna well controlled, reduced use of hydrocortisone. 25/11/98: Had flare up of eczerna. Altoderm caused stinging sensan treated with hydrocortisone. Altoderm OK again after one day Treastopped early 1999 as skin clear	Notes

Received from							
	None	4% Lotion	December 2002	Atopic dermatitis	19/11/95	HS	40
	Emollients	4% lotion	March 2002	Atopic dermatitis	4 years	S	39
	Hydrocortisone 1%	4% lotion	November 2002	Atopic dermatitis	22/10/96	DK	38.
	Hydrocortisone 1%	4% lotion	November 2002	Atopic dermatitis	07/12/98	JH	37.
	Hydrocortisone 1%	4% lotion	November 2002	Atopic dermatitis	20/03/00	H	36
Ì	None	4% Lotion	September 2002	Atopic dermatitis	3 years	Ç	35
픠	Haelen (steroid cream)	4% lotion	December 2002	Atopic dermatitis	10/09/98	JF	34 -
	Hydrocortisone	4% lotion	November 2002	Atopic dermatitis	27/09/92	ଧ	33.
	None	4% lotion	October 2002	Atopic dermatitis	12/12/98	ZF	32
	Fucidin (antibiotic)	4% lotion	November 2002	Atopic dermatitis	04/07/91	CG	31
	Fucibet (steroid)	4% lotion	November 2002	Atopic dermatitis	15/07/93	Mβ	30
	None	4% Lotion	November 2002	Atopic dermatitis	02/05/93	SW	29
ľ	None	4% lotion	November 2002	Atopic dermatitis	03/08/96	WT	28.
İ	None	4% Lotion	November 2002	Atopic dermatitis	23/02/95	CD-B	27.
	None	4% lotion	October 2002	Atopic dermatitis	26/09/97	IP	26.
	Hydrocortisone	4% lotion	October 2002	Atopic dermatitis	06/02/00	gri	25
	Hydrocortisone	4% lotion	October 2002	Atopic dermatitis	06/02/00	ВО	24.
	None	4% lotion	Јапиагу 2003	Atopic dermatitis	6/4/93	WA	23.
	Filmovate	4% lotion	November 2002	Atopic demantis	03/05/98	WT	22
	Hydrocortisone	4% lotion	May 2002	Eczema	23/10/99	RH	21
	None	4% Intion	October 2002	Eczema	16/6/63	EC	25
	None	4% 10tion	30/2/03	Atonic dematitie	7/10/00	EW.	24
		4% lotion	31/1/02	Atopic dermatitis	30/4/63	35	22
	None	4% lotion	May 2003	Dermatitis	Aged 51	7	2 2
	None	4% lotion	Jan 2002	Eczema	20/12/95	ER.	20
	None	4%lotion	Jan 2002	Contact dermatitis	15/9/52	AUB	19
	None	4%lotion	Feb 2002	Mild facial eczema	C8/111/7	N H	~
	None	4 % Lotion	Sept 2002	? cause	20/0/03	*	5 5
	None	4% lotion	June 2002	Atopic demants	3616163	£ {	1 6
	Sterolds	470 1011011	Copicinosi 2001	A Respect Constitution	5000	3	5
	Notic	40/ lotion	TOOL TOOL	Atonio dermotitic	15/4/89	AM	-
	None	40% Intion	August 2002	Facial eczema	2/10/56	SS	14
ļ	treatment	of Altoderm	commenced	· ÷.	birth		200

EXHIBIT E

I

Eur J Pediatr (1989) 149: 74

european Journal of
Pediatrics
© Springer-Verlag 1989

Letter to the editors

Nedocromil sodium cream in the treatment of atopic dermatitis

H.P. Van Bever and W.J.Stevens

Departments of Psediatrics and Immunology, University Hospital Antwerp, 8-2520 Antwerp, Belgium

Sir: There have been a number of studies on the, effect of topical sodium cromoglycate in atopic dermatitis. In most of these studies topical sodium cromoglycate failed to show any significant activity [2, 4].

Recently, nedocromil sodium was developed. This drug showed activity similar to that of sodium eromoglycate but is markedly more potent [1].

Since mast cell involvement has been observed at some stage in the development of various skin disease including atopic dermatitis [3], nedocromil sodium seems to be an obvious candidate for investigation in the area of atopic dermatitis.

Therefore, we undertook a double-blind, parallel group trial in which following a 2-week baseline period, atopic dermatitis patients were assigned randomly to either a 4% nedocromit sodium cream or a placebo for 4 weeks. The cream (nedocromit sodium or placebo) was applied twice daily. For dermal application, nedocromit sodium was formulated as an oil-in-water cream, stabilised with glyceryl monostearate and cetostearyl alcohol. It was maintained at pH 5.6 (= skin surface pH) by a sodium acid citrate/sodium hydroxide buffer, and preserved using a combination of parabens and potassium sorbate. In skin permeation tests using hairless mouse skin in vitro, a penetration rate of 2µg/cm² per hour of nedocromit sodium, was observed. As placebo, the same cream was used but without nedocromit sodium. Both preparations were: kindly supplied by Fisons Pharmaceuticals, Loughborough, England.

Twenty-six patients with atopic dermatitis (13/26 patients were between the age 12-16 years) entered the: trial of whom 2 dropped out during the baseline period.

The 2 treatment groups (2 x 12 patients) were similar according to; sex, age (mean: 16 years, range: 12-47 years), weight, duration of atopic dermatitis, severity of atopic dermatitis during the last 12 months, present severity at the start of the trial and co-existence of bronchial asthma.

Evaluation of the treatment was performed using:

I. A daily score card for severity of atopic dermatitis was completed using a four-point score for day itching, night itching, sleep and overall severity of the skin lesions. For each treatment mean scores were computed for the baseline period, weeks 1 and 2 of the treatment and weeks 3 and 4 of the treatment. The differences of the final period from the baseline for the two treatments were compared by the Mann Whitney U-test.

- Clinical examination every 2 weeks during the trial, using a physician's five-point score for the severity of skin lesions.
- The frequence of the use of an "escape." treatment (a 1 % hydrocortisone containing cream).

Remits

During the treatment phase, nine patients were withdrawn. Six (four on placebo) of these due to a gradual deterioration of the atopic dermatitis. Two (one on each treatment) due to a rapid deterioration, and one on nedocromil sodium because of a suspected adverse reaction (increased dryness of the skin).

By the use of the daily symptom score, no significant difference could be detected between the two treatments (Mann-Whitney U-test).

After 4 weeks treatment both patients and clinician could not detect any difference between the two treatments using a five-point score. The two groups showed also the same usage of the escape treatment.

Seventeen episodes of flaring of symptoms were recorded during the active treatment period, 9 of these were in the patients treated with nedocromil sodium. One caused withdrawal from the trial because of dryness of the skin in a patient treated with nedocromil sodium and one caused treatment to be stopped for 6 days because of furunculosis. This was observed in a patient treated with placebo. However, the most common symptoms were exacerbations of atopic dermatitis and itching.

In conclusion, 4% nedocromil sodium cream, applied duing 4 weeks, twice daily has no advantage over placebo in the treatment of patients (older children and adults) with stopic dermatitis. No data are yet available on the use of nedocromil sodium cream in young children with atopic dermatitis.

References

1. Eady RP (1986) The pharmacology of nedocromil sodium. Eur J

Respir Dis (Suppl) 69: 112-119
2, Haider SA (1977) Treatment of atopic eczema in children: clinical trial of 10% sodium eromoglycate ointment, Br Med J i: 1570-1572
3. Haniffn JM (1984) Atopic dermatitis. J Allergy Clin Immunol 73: 211-222

4, Thirumoothy T, Greaves MW (1978) Disodhum cromoglycate ointment in atopic eczema. Br Med J ii: 500-501

Received March 15, 1989 / Accepted May 25, 1989